Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: Results from the RISCAVID study

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2641-2648

  Panichi, Vincenzo ^a   Rosati, Alberto ^b   Bigazzi, Roberto ^c   Paoletti, Sabrina ^a   Mantuano, Emanuela ^c   Beati, Sara ^a   Marchetti, Valentina ^d   Bernabini, Giada ^a   Grazi, Giovanni ^e   Rizza, Giovanni Manca ^e   Migliori, Massimiliano ^a   Giusti, Riccardo ^b   Lippi, Alberto ^f   Casani, Aldo ^g   Barsotti, Giuliano ^d   Tetta, Ciro ^h  

^a Nephrology and Dialysis Versilia Hospital   (Italy)

^b Nephrology and Dialysis   (Italy)

^c Nephrology and Dialysis   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e Fresenius Medical Care ^*  (Italy)

^f Nephrology and Dialysis   (Italy)

^g Nephrology and Dialysis   (Italy)

^h Fresenius Medical Care   (Germany)

Author keywords

anaemia; C reactive protein; cytokines; erythropoietin resistance index; haemodialysis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SEVELAMER;

AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FATALITY; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

AGED; ANEMIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; PROGNOSIS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 79958180106     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq802     Document Type: Article

References (26)

1. Eckardt KU. Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant 2005;20(Suppl 6):vi16-vi20
2. Regidor DL, Kopple JD, Kovesdy CP et al. Association between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191
3. Levin A. The relationship of haemoglobin level and survival: direct or indirect effects? Nephrol Dial Transplant 2002;17(Suppl 5):8-13 (Pubitemid 34823066)
4. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008;3:200-207
5. Stivelman JC. Refractoriness to recombinant human epoetin (rHuEPO) treatment. In: Nissenson AR, Fine RN, eds. Handbook of Dialysis Therapy. 4th edn. Philadelphia, PA: Saunders Elsevier; 2008:812-831
6. Stenvinkel P, Bárány P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. Nephrol Dial Transplant 2002;17(Suppl 5):32-37 (Pubitemid 34823070)
7. Locatelli F, Aljama P, Bárány P et al. European Best Practice Guidelines Working Group: revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-ii47
8. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S11-17
9. Tsai A, Berns JS. Use of erythropoietic-stimulating agents in hemodialysis patients. In: Nissenson AR, Fine RN, eds. Handbook of dialysis therapy. 4th edn. Philadelphia, PA: Saunders Elsevier; 2008:771-785
10. Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents-what do we know and what needs to be clarified? Nephrol Dial Transplant 2005;20(Suppl 8):viii2-viii7
11. Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 2005;35(Suppl 3):32-35 (Pubitemid 41783602)
12. Panichi V, Rizza GM, Paoletti S et al. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 2008;23:2337-2343 (Pubitemid 351957592)
13. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077-1083
14. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoietin-a dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-798
15. Singh AK, Coyne DW, Shapiro W et al. Predictors of the response to treatment in anemic haemodialysis patients with high serum ferritin and low transferring saturation. Kidney Int 2007;71:1163-1171 (Pubitemid 46809141)
16. Bradbury BD, Critchlow CV, Weir MR et al. Impact of elevated C-reactive protein levels on Erythropoiesis-stimulating agent (ESA) dose and responsiveness in haemodialysis patients. Nephrol Dial Transplant 2009;24:919-925
17. Bárány P, Divino Filho JC, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997;29:565-568 (Pubitemid 27155278)
18. Gunnell J, Yeun JY, Depner TA et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63-72 (Pubitemid 29031210)
19. Panichi V, Maggiore U, Taccola D et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in hemodialysis patients. Nephrol Dial Transplant 2004;19:1154-1160 (Pubitemid 38628135)
20. Goicoechea M, Martin J, de Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998;54:1337-1343 (Pubitemid 28449924)
21. Cooper AC, Mikhail A, Lethbridge MW et al. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003;14:1776-1784 (Pubitemid 36750473)
22. Girndt M, Stenvinkel P, Ulrich C et al. Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients. Nephrol Dial Transplant 2007;22:3586-3592 (Pubitemid 350212475)
23. Carrero JJ, Ortiz A, Qureshi AR et al. Additivie effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:110-118
24. Shantouf R, Ahmadi N, Tiano J et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in haemodialysis patients. Am J Nephrol 2008;28:275-279
25. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33-50 (Pubitemid 46722293)
26. Yeun JY, Levine RA, Mantadilok V et al. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-476 (Pubitemid 30124077)